Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Water | HCID 962 | — |
| Reactant | 1,8-Diazabicyclo(5.4.0)undec-7-ene | HCID 81184 | — |
| Reactant | 2-fluoro-5-(1H-1,2,3-triazol-1-yl)pyridine | HCID 58128556 | — |
| Reactant | 2-{(1S,2S)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}ethanamine | HCID 67778474 | — |
| Solvent | N-methyl-2-pyrrolidone | HCID 13387 | — |
| Product | HCID 50939660 | HCID 50939660 | — |
Reaction Steps
2-{(1S,2S)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}ethanamine (30 mg, 0.11 mmol) from Example 2 step 3 was dissolved in NMP (0.21 mL), DBU (24.4 mg, 0.16 mmol) was added, stirred at room temperature for 10 minutes. 2-fluoro-5-(1H-1,2,3-triazol-1-yl)pyridine (21 mg, 0.13 mmol; from step 2 of this example) was added. Reaction was heated to 110° C. for 3 hours. The reaction was cooled down to room temperature, water (10 mL) was added, extracted with EtOAc (10 mL×2), second wash with Brine (10 mL). The organic phase was dried by magnesium sulfate, filter, concentrated and purified by column chromatography through a 12 gram RediSep Rf™ silica gel cartridge eluting with 30% ethylacetate/hexanes to give the title compound as a white solid.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08552022B2 |
|---|
| Source dataset | uspto-grants-2013_10 |
|---|
| ORD ID | ord-e9d17d8f939d4af9be55b205fb2c5a0a |
|---|
| Source note | uspto-grants-2013_10 |
|---|